XST-14

Item no.	HY-137506-25mg
Manufacturer	MedChem Express
CASRN	2607143-50-8
Amount	25 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 25 mg 50 mg 5 mg
Category	Reagents & Chemicals Biochemicals
Type	Biochemicals
Specific against	other
Purity	99.26
Citations	[1]Si-Tu Xue, et al. The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target . Autophagy. 2020 Oct;16(10):1823-1837.
Smiles	O=C(OC)C1=CC2=C(OC(C)C)C=C(OC(C)C)C=C2N1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Anaplastic lymphoma kinase (ALK); Apoptosis; CaMK; p38 MAPK; TGF-β Receptor; ULK
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	291.34
Product Description	XST-14 is a potent, competitive and highly selective ULK1 inhibitor with an IC50 of 26.6 nM. XST-14 induces autophagy inhibition by reducing the phosphorylation of the ULK1 downstream substrate. XST-14 induces apoptosis in hepatocellular carcinoma (HCC) cells and has antitumor effects[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 250 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis; Autophagy; MAPK/ERK Pathway; Neuronal Signaling; Protein Tyrosine Kinase/RTK; TGF-beta/Smad
Isoform	CaMK II; ULK1
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-137506-25mg-safety-datasheet.pdf